Combination therapy
By using a combination of isoquinoline compounds and prostaglandins or prostaglandin analogs, and administering it topically to patients, the problems of controlling elevated intraocular pressure and treating glaucoma have been solved, achieving effective treatment results in reducing intraocular pressure and minimizing side effects.
Patent Information
- Application Number
- CN201910531443.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2013-03-15
- Filing Date
- 2014-03-14
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2034-07-06
AI Technical Summary
Current technologies are insufficient to effectively control elevated intraocular pressure, which leads to glaucoma damage, and there is a lack of treatments without side effects.
Glaucoma is treated by topically administering a composition comprising isoquinoline compounds and prostaglandins or prostaglandin analogs to a subject to reduce intraocular pressure.
It effectively lowers intraocular pressure, reduces glaucoma damage, and provides a treatment method with no obvious side effects.
Smart Images

Figure CN110396085B_ABST
Abstract
Description
[0001] This application is a divisional application of the invention patent application "Combination Therapy" with application date of March 14, 2014 and application number 201480027763.3 (PCT / US2014 / 029335).
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Application Serial No. 61 / 787,883, filed March 15, 2013, which is incorporated herein by reference in its entirety. Technical Field
[0004] The present invention relates to combination therapy. The present invention describes compounds and compositions for treating glaucoma and / or reducing intraocular pressure. Background Art
[0005] Many ophthalmic conditions are caused by, or are exacerbated by, damage to the optic nerve head, degeneration of ocular tissue, and / or elevated intraocular pressure (IOP). For example, "glaucoma" is a group of debilitating eye diseases that are the leading cause of irreversible blindness in the United States and other developed countries. There is a continuing need for treatments that control elevated IOP to limit glaucomatous damage without undesirable side effects. Summary of the invention
[0006] In one aspect, the present disclosure may provide a composition comprising:
[0007] a) a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0008]
[0009] in:
[0010] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0011] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0012] Each R 10independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted; and
[0013] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0014] b) a prostaglandin or a prostaglandin analog or a pharmaceutically acceptable salt thereof.
[0015] In another aspect, the present disclosure may provide a compound of formula (II) or a pharmaceutically acceptable salt thereof:
[0016]
[0017] in:
[0018] Y is selected from alkylene, aryl, heteroaryl, cycloalkyl and heterocyclyl, any of which may be optionally substituted;
[0019] B is selected from -NR1R2, -CH2NR1R2, -CH(R 10 )R2、-CCH3(R 10 )R2, -NHCH(R 10 )R2, -N(CH3)R2, -CH2CH2R2, -CH(R 10 )CH2R2 and -CH2CH(R 10 )R2;
[0020] R1, R2 and R 10 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, any of which may be optionally substituted;
[0021] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0022] PG is the acyl group of a prostaglandin or a prostaglandin analog.
[0023] In another aspect, the present disclosure may provide a compound of formula (III):
[0024]
[0025] in:
[0026] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0027] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0028] Each R 10 independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted;
[0029] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0030] It is the deprotonated free acid of prostaglandin or prostaglandin analog.
[0031] In another aspect, the present disclosure may provide a composition comprising:
[0032] a)(rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0033] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0034] In another aspect, the present disclosure may provide a composition comprising:
[0035] a) (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0036] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0037] In another aspect, the present disclosure may provide a composition comprising:
[0038] a) (S)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0039] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl Ester PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0040] In another aspect, the present disclosure may provide a composition comprising:
[0041] a) (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dimethanesulfonate; and
[0042] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0043] In another aspect, the present disclosure may provide a composition comprising:
[0044] a) (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0045] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0046] In another aspect, the present disclosure may provide a composition comprising:
[0047] a) (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0048] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0049] In another aspect, the present disclosure may provide a composition comprising:
[0050] a)(rac)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0051] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0052] In another aspect, the present disclosure may provide a composition comprising:
[0053] a) (R)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0054] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0055] In another aspect, the present disclosure may provide a composition comprising:
[0056] a) (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0057] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0058] In another aspect, the disclosure may provide a method of treating an ophthalmic condition in a subject in need of treatment, the method comprising administering to the subject a compound or composition described herein. In some embodiments, the ophthalmic condition is glaucoma.
[0059] In another aspect, the disclosure may provide a method of reducing intraocular pressure in a subject in need thereof, the method comprising topically administering to an eye of the subject a compound or composition described herein.
[0060] In another aspect, the present disclosure may provide a compound selected from the group consisting of:
[0061] a) (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate;
[0062] b) (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0063] c) (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate.
[0064] Other aspects and embodiments of the disclosure will become apparent upon consideration of the following description. BRIEF DESCRIPTION OF THE DRAWINGS
[0065] Figure 1 is a graph showing the intraocular pressure after administration of the composition described in Example 4.
[0066] Figure 2 is a graph showing the intraocular pressure after administration of the composition described in Example 5.
[0067] Figure 3 is a graph showing the intraocular pressure after administration of the composition described in Example 8. DETAILED DESCRIPTION
[0068] Described herein are pharmaceutical compositions comprising an isoquinoline compound (e.g., a compound of formula (I)) and a prostaglandin or a prostaglandin analog or a pharmaceutically acceptable salt thereof (e.g., latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2α Also described herein are compounds of formula (II) comprising an isoquinoline compound covalently linked to a prostaglandin or a prostaglandin analog and compounds of formula (III) as salts of an isoquinoline compound and a prostaglandin or a prostaglandin analog free acid. Such compounds and compositions are useful, for example, in treating ophthalmic conditions (e.g., glaucoma) by reducing intraocular pressure.
[0069] Before describing in detail any embodiment of the present disclosure, it should be understood that in the present application, the present disclosure is not limited to the details of the structure and arrangement of the components shown in the following description or illustrated in the accompanying drawings. The present disclosure can have other embodiments and can be implemented or completed in a variety of ways. It should also be understood that the wording and terminology used herein are for illustrative purposes and should not be considered as restrictive. "Including", "comprising" or "having" and their variations are intended to cover the items listed thereafter and their equivalents and other items.
[0070] definition
[0071] The definitions of specific functional groups and chemical terms are described in more detail below. For the purposes of this disclosure, chemical elements are identified according to the CAS version of the Periodic Table of the Elements on the inside cover of the Handbook of Chemistry and Physics, 75th edition, and the definitions of specific functional groups are primarily as described herein. In addition, general principles of organic chemistry as well as specific functional moieties and reactivities are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March March's Advanced Organic Chemistry, 5th edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; Carruthers, Some Modern Methods of Organic Synthesis, 3 rd Edition, Cambridge University Press, Cambridge, 1987; the entire contents of each of which are incorporated herein by reference.
[0072] "Acyl" or "carbonyl" refers to the group -C(O)R, where R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocyclylalkyl, any of which may be optionally substituted, e.g., with one or more substituents. For example, when R is alkyl, such a group may be referred to as alkylcarbonyl.
[0073] As used herein, "administering" means giving a compound as needed to achieve a desired effect.
[0074] "Alkyl" refers to a group -OR, where R is alkyl, alkenyl, alkynyl, cycloalkyl or heterocyclyl, any of which may be optionally substituted, for example, by one or more substituents.
[0075] "Alkyl" refers to a saturated aliphatic hydrocarbon chain which may be straight or branched. The alkyl group may have the indicated number of carbon atoms. For example, C1-C 12 Alkyl refers to an alkyl group having 1 to 12 (inclusive) carbon atoms. C1-C4 alkyl refers to an alkyl group having 1, 2, 3 or 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl or tert-butyl. Alkyl may be optionally substituted, for example by one or more substituents.
[0076] "Alkylene" refers to a divalent alkyl group, for example -CH2-, -CH2CH2-, -CH2CH2CH2-, or -CH2CH(CH3)CH2-. An alkyl or alkylene group may be optionally substituted, for example, by one or more substituents.
[0077] "Alkenyl" refers to a straight or branched hydrocarbon chain having one or more double bonds. Alkenyl groups may have the indicated number of carbon atoms. For example, C2-C 12 Alkenyl refers to an alkenyl group having 2-12 (inclusive) carbon atoms. C2-C4 alkenyl refers to an alkenyl group having 2, 3 or 4 carbon atoms. Examples of alkenyl groups include, but are not limited to, allyl, propenyl, 2-butenyl, 3-hexenyl and 3-octenyl. One of the double bond carbons may optionally be the point of attachment of the alkenyl substituent. The term "alkenylene" refers to a divalent alkenyl group, such as -CH=CH-, -CH=CH2CH2- or -CH=C=CH-. Alkenyl or alkenylene may be optionally substituted, such as by one or more substituents.
[0078] The term "alkynyl" refers to a straight or branched hydrocarbon chain having one or more triple bonds. Alkynyl groups may have the indicated number of carbon atoms. For example, C2-C 12 Alkynyl refers to an alkynyl group having 2-12 (inclusive) carbon atoms. C2-C4 alkynyl refers to an alkynyl group having 2, 3 or 4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl and 3-hexynyl. One of the triple bond carbons may optionally be the point of attachment of an alkynyl substituent. The term "alkynylene" refers to a divalent alkynyl group. For example, -C≡C- or -C≡C-CH2-. Alkynyl or alkynylene groups may be optionally substituted, for example, by one or more substituents.
[0079] "Amino" refers to the group -NR'R", where R' and R" are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R' and R" can be taken together with the nitrogen to which they are attached to form a ring. Examples of amino groups include, but are not limited to: -NH2; alkylamino groups such as -NHCH3, -NHCH2CH3 and -NHCH(CH3)2; dialkylamino groups such as -N(CH3)2 and -N(CH2CH3)2; and arylamino groups such as -NHPh. Examples of cyclic amino groups include, but are not limited to, aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperazinyl, perhydrodiazepines, cyclopentadienyl ... The groups R' and R" may be optionally substituted, for example by one or more substituents, or when R' and R" together with the nitrogen to which they are attached form a ring, the ring may be optionally substituted, for example by one or more substituents.
[0080] "AR-102" refers to the compound 3-hydroxy-2,2-bis(hydroxymethyl)propyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]-thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate. "AR-102 free acid" refers to the compound 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoic acid.
[0081] "Aryl" refers to an aromatic monocyclic, bicyclic, or tricyclic hydrocarbon ring system in which any substitutable ring atom may be substituted (e.g., by one or more substituents). Substituents may be located at various positions on the aryl group. For example, substituents on a phenyl group may be located at the ortho position, meta position, para position, or a combination thereof. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and anthracenyl.
[0082] "Arylalkyl" refers to an alkyl group in which an alkyl hydrogen atom is replaced with an aryl group. Arylalkyl groups include groups in which more than one hydrogen atom is replaced with an aryl group. Examples of arylalkyl groups include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, 9-fluorenyl, diphenylmethyl, and triphenylmethyl. Arylalkyl groups may be optionally substituted, for example, with one or more substituents, on the alkyl portion or the aryl portion of the arylalkyl group.
[0083] "Aryloxy" refers to a group -OR, where R is aryl or heteroaryl, which may be optionally substituted, for example, with one or more substituents.
[0084] "Buffer" or "buffer system" refers to a compound or combination of compounds that provide a buffer system in a solution that exhibits a buffering capacity, i.e., the ability to moderately neutralize an acid or base with relatively little or no change in the original pH. The term "buffering capacity" is defined as the number of millimoles (mM) of a strong acid or base (or, respectively, hydrogen ions or hydroxide ions) required to change the pH by 1 unit when added to 1 liter (standard unit) of a buffer solution. The buffering capacity will depend on the type and concentration of the buffer components.
[0085] "Carboxyl" refers to the group -C(=O)OR, where R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted, for example by one or more substituents.
[0086] "Carbonylamino" or "amido" refers to the group -C(O)NR'R", where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R' and R" may be taken together with the nitrogen to which they are attached to form a ring. The groups R' and R" may be optionally substituted, for example with one or more substituents, or when R' and R" are taken together with the nitrogen to which they are attached to form a ring, the ring may be optionally substituted, for example with one or more substituents.
[0087] "Cycloalkyl" refers to a non-aromatic saturated or partially unsaturated monocyclic, bicyclic, tricyclic or polycyclic hydrocarbon group. Cycloalkyl may include about 3 to about 12 carbon atoms. For example, a monocyclic cycloalkyl may include 3 to 10 carbon atoms, such as 3, 4, 5, 6, 7 or 8 carbon atoms. A bicyclic carbocyclic group contains 8 to 12 carbon atoms, such as 9 or 10 carbon atoms. Any ring atom may be substituted (e.g., by one or more substituents). Cycloalkyl includes condensed, spiral and bridged bicyclic ring systems. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, methylcyclohexyl, adamantyl, norbornyl and norbornenyl.
[0088] As used herein, "cycloalkylalkyl" refers to an alkyl group substituted with a cycloalkyl group.
[0089] "Excipient" refers to a physiologically compatible additive useful in preparing a pharmaceutical composition. Examples of pharmaceutically acceptable carriers and excipients can be found, for example, in Remington Pharmaceutical Science, 16 th Ed.
[0090] As used herein, "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen, including alkyl moieties in which all hydrogens are replaced by halogens (eg, perfluoroalkyl groups, such as CF3).
[0091] "Halogen" or "halo" refers to a fluorine, chlorine, bromine or iodine moiety.
[0092] "Heteroalkyl" refers to an alkyl group as defined herein, wherein at least one carbon atom of the alkyl group is replaced with a heteroatom. Suitable heteroalkyl groups include, but are not limited to, methoxymethyl (-CH2-O-CH3).
[0093] "Heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic, or tricyclic ring having one or more heteroatoms. For example, a heteroaryl can be an aromatic 5-8 membered monocyclic ring having 1-4 heteroatoms, an 8-12 membered bicyclic ring having 1-6 heteroatoms, or an 11-14 membered tricyclic ring system having 1-9 heteroatoms. A heteroaryl group can contain fused rings, which are rings that share one or more common atoms. Any ring atom that is capable of substitution can be substituted (e.g., by one or more substituents). Examples of heteroaryl groups include, but are not limited to, tetrazolyl, triazolyl, thienyl, thiazolyl, isothiazolyl, purinyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, furanyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, indolyl, isoindolyl, indolizinyl, indazolyl, imidazolyl, phthalazinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, acridinyl, phenanthrolinyl, phenazinyl, and naphthyridinyl.
[0094] The term "heteroarylalkyl" as used herein refers to an alkyl group substituted with a heteroaryl group.
[0095] "Heteroatom" refers to an atom other than carbon in the ring of a heterocyclic or heteroaromatic group or in the chain of a heteroalkyl group. For example, the heteroatom may be selected from nitrogen, oxygen, silicon, phosphorus and sulfur. Particularly suitable heteroatoms are nitrogen, oxygen and sulfur. Groups containing more than one heteroatom may contain different heteroatoms.
[0096] "Heterocyclyl" or "heterocycloalkyl" refers to a non-aromatic saturated or partially unsaturated hydrocarbon ring system containing at least one heteroatom. Heterocyclyl groups may contain from about 3 to about 12 member atoms. For example, a monocyclic cycloalkyl group may contain from 3 to 10 member atoms, such as 3, 4, 5, 6, 7 or 8 member atoms. Bicyclic carbocyclic groups contain from 8 to 12 member atoms, such as 9 or 10 member atoms. Any ring atom capable of substitution may be substituted (e.g., by one or more substituents). Heterocyclyl includes fused, spiro and bridged bicyclic ring systems. Examples of heterocyclic groups include, but are not limited to, epoxy, tetrahydrofuranyl, homopiperidinyl, tetrahydrothiophenyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, pyrrolinyl, pyrimidinyl, pyrrolidinyl, dihydroindolinyl, tetrahydropyridinyl, dihydropyran, thianthrene, pyran, benzopyran, xanthene, phenoxathiin, phenothiazinyl, furazanyl, lactones, lactams (e.g., azetidinone and pyrrolidone), sultams, sultones, and the like.
[0097] The term "heterocyclylalkyl" or "heterocycloalkylalkyl" as used herein refers to an alkyl group substituted with a heterocyclyl group.
[0098] "Hydroxy" or "hydroxyl" refers to the group -OH.
[0099] "Linker" means a chain of n member atoms, where n is an integer from 1-4.
[0100] "Member atom" means a carbon, nitrogen, oxygen or sulfur atom. Member atoms may be substituted up to their normal valence.
[0101] The term "mercapto" or "thiol" refers to a -SH group. "Thioalkyl" or "thioether" refers to an -S-alkyl group. The term "thioaryloxy" refers to an -S-aryl group.
[0102] As used herein, the term "ophthalmic disorder" includes, but is not limited to, glaucoma, allergy, cancer of the eye, neurodegenerative disease of the eye, dry eye disease, and corneal epithelial damage. "Methods of treating ophthalmic disorders" may refer to methods of treating glaucoma, allergy, cancer of the eye, neurodegenerative disease of the eye, dry eye disease, and corneal epithelial damage, or may refer to methods of protecting retinal ganglion cells.
[0103] The term "oxo" refers to an oxygen atom which forms a carbonyl when attached to carbon, an N-oxide when attached to nitrogen, and a sulfoxide or sulfone when attached to sulfur. The term "thio" refers to a sulfur atom which forms a thiocarbonyl when attached to carbon.
[0104] "Phosphonate" refers to -P(O)(OR)2, wherein each R is independently selected from hydrogen, alkyl, alkenyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, each of which may be optionally substituted, for example, with one or more substituents.
[0105] "Prostaglandins" are any compounds with a prostanoic acid skeleton:
[0106]
[0107] "Prostaglandin analogs" refer to compounds that have the potential to bind to prostaglandin receptors. Prostaglandin analogs include protected prostaglandins or prostaglandin prodrugs, such as prostaglandins with esters or amides at the C1, C9, C11 and / or C15 positions.
[0108] "Prostaglandin free acid" refers to a prostaglandin or prostaglandin analog having a carboxylic acid at the C1 position.
[0109] "Prostaglandin F analogues", "PGF analogues" or "PGF 2α "Analogues" refer to PGF 2α Similar compounds have the potential to bind to and activate prostaglandin F-type receptors. F-type receptors include, but are not limited to, FP receptors.
[0110] "Prostaglandin E analogs", "PGE analogs", "analogs of PGE2" or "analogs of PGE1" refer to compounds that are generally structurally similar to naturally occurring PGE2 or PGE1 and have the potential to bind to and activate prostaglandin E-type receptors. E-type receptors include, but are not limited to, EP1, EP2, EP3 and EP4 receptors.
[0111] "Prostaglandin D analogs", "PGD analogs" or "PGD2 analogs" refer to compounds that are generally structurally similar to naturally occurring PGD2 and have the potential to bind to and activate prostaglandin D-type receptors. D-type receptors include, but are not limited to, DP1 and EP2 receptors.
[0112] "Ring" means a cyclic group of member atoms. The ring may be carbocyclic, aromatic or heterocyclic or heteroaromatic, may be substituted or unsubstituted, and may be saturated or unsaturated. The junction of the ring with the main chain may be fused or spirocyclic. The ring may be monocyclic or bicyclic. The ring contains at least 3 member atoms and at most 12 member atoms. A monocyclic ring may contain 3-10 member atoms, while a bicyclic ring may contain 8-12 member atoms. A bicyclic ring itself may be fused or spirocyclic. The ring may be optionally substituted or unsubstituted, for example by one or more substituents.
[0113] As used herein, "ROCKi" refers to an inhibitor of Rho-associated protein kinase (ROCK).
[0114] "Substituent" refers to a "substituted" group on a group such as alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, which is located on any suitable atom of the former. Suitable substituents include, but are not limited to, acyl, alkoxy, alkyl, alkenyl, alkynyl, amino, aryl, arylalkyl, carbonylamino, carboxyl, cycloalkyl, cycloalkylalkyl, cyano, halogen, haloalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, hydroxy, nitro, oxo (e.g., C=O), phosphonate, sulfinyl, sulfonyl, sulfonate, sulfonamido, thioamido, thiol, thioalkyl, thio (e.g., C=S) and urea. In an embodiment, the substituent on the group is independently any single group or any combination of the aforementioned substituents. In an embodiment, the substituent itself may be substituted by any of the above-mentioned substituents.
[0115] The above substituents may be abbreviated herein. For example, the abbreviations Me, Et, Ph, Bn, and Ac represent methyl, ethyl, phenyl, benzyl, and acetyl, respectively. A more comprehensive list of abbreviations used by organic chemists of ordinary skill in the art is found in the first issue of each volume of the Journal of Organic Chemistry; this list is usually found in a table named Standard List of Abbreviations. The abbreviations contained in the above list and all abbreviations used by organic chemists of ordinary skill in the art are incorporated herein by reference.
[0116] "Sulfinyl" refers to a -S(=O)R radical where R is selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocyclylalkyl, any of which can be optionally substituted (e.g., with one or more substituents).
[0117] “Sulfonic acid” and “sulfonate ester” refer to –S(O)2OH and –S(O)2O, respectively. - Group.
[0118] "Sulfonyl" refers to a -S(O)2R radical where R is selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocyclylalkyl, any of which can be optionally substituted (e.g., with one or more substituents).
[0119] "Sulfonamido" refers to a -S(O)2NR'R" radical where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, and heterocyclylalkyl, any of which can be optionally substituted (e.g., with one or more substituents).
[0120] "Therapeutically effective amount" refers to a dose of a compound or composition that effectively affects, reduces or inhibits kinase activity or prevents its activation. As used herein, the term may also refer to an amount effective to bring about a desired in vivo effect (e.g., lowering intraocular pressure) in an animal (preferably a human).
[0121] "Thioalkyl" refers to the group -S-alkyl.
[0122] "Thioamido" refers to -C(S)NR'R", wherein R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, or R' and R" may be taken together with the nitrogen to which they are attached to form a ring. The groups R' and R" may be optionally substituted, for example with one or more substituents, or when R' and R" are taken together with the nitrogen to which they are attached to form a ring, the ring may be optionally substituted, for example with one or more substituents.
[0123] As used herein, "treating" refers to administering a regimen to a subject, such as administering a compound or composition described herein, so as to cure, alleviate, relieve, alter, mitigate, improve, and / or modify a condition or at least one symptom of the condition. Treatment includes administering an amount effective to alleviate, mitigate, alter, mitigate, improve, modify, and / or affect a condition or a symptom of the condition. Treatment may inhibit the worsening or worsening of the symptoms of the condition.
[0124] "Urea" refers to -N(R)C(O)NR'R", wherein each R, R' and R" is independently selected from hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, heterocyclyl, heteroaryl, arylalkyl, cycloalkylalkyl, heteroarylalkyl and heterocyclylalkyl, any of which may be optionally substituted (e.g., with one or more substituents).
[0125] When substituents are specified by their conventional chemical formula written from left to right, they optionally encompass substituents resulting from writing the structure from right to left, e.g., -CH2NH- is optionally also written as -NHCH2-. Although certain substituent lists include groups shown in two orientations, it is expressly understood that any substituent written in a particular orientation (e.g., left to right) also encompasses the same group in another orientation (e.g., right to left).
[0126] According to the convention used in the art, the following groups are used in the formulae herein to describe the bond that serves as the point of attachment of a moiety or substituent to a core or backbone structure:
[0127]
[0128] For the compounds described herein, groups and substituents thereof are chosen based on the allowed valencies of atoms and substituents so that stable compounds are selected and substituted, e.g., compounds that do not spontaneously transform (e.g., by rearrangement, cyclization, elimination, etc.).
[0129] It should be particularly understood that any numerical range recorded herein includes all values from the lower limit to the upper limit. For example, if the concentration range is recorded as 1%-50%, it means that values such as 2%-40%, 10%-30% or 1%-3% are explicitly listed in this specification. They are just examples of specific meanings, and all possible combinations of values between and including the lowest and highest values listed are deemed to be explicitly recorded in this application.
[0130] All percentages, ratios and proportions used herein are % weight / volume (% wt / vol or w / v) unless otherwise specified.
[0131] Compound
[0132] Compounds useful in the compositions described herein include isoquinoline compounds. Such compounds and compositions comprising them may have kinase inhibitory activity and may therefore be used to affect or inhibit kinase action and treat and / or prevent diseases or conditions affected by kinases. Exemplary kinases that may be affected include, but are not limited to, ROCK-I, ROCK-II, PKA, PKC, CAM kinases, GRK-2, GRK-3, GRK-5, or GRK-6. For example, the inhibited kinase may be a Rho-associated protein kinase (ROCK).
[0133] Isoquinoline compounds useful in the compositions and methods described herein include compounds of formula (I) or pharmaceutically acceptable salts thereof:
[0134]
[0135] in:
[0136] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0137] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0138] Each R 10 independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted; and
[0139] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio and carboxyl.
[0140] In some embodiments of Formula (I), X1 is hydrogen, X2 is hydroxy, R1 is alkyl (e.g., methyl), R2 is alkyl (e.g., methyl), A is -CH (R 10 )-, and R 10 is an aryl group (eg, phenyl).
[0141] In some embodiments of formula (I), X1 is hydrogen, X2 is hydroxy, R1 and R2 are taken together to form a heterocyclyl ring, and A is -CH(R 10 )-, and R 10 It is an alkyl group.
[0142] In some embodiments of Formula (I), X1 and X2 are hydrogen, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0143] In some embodiments of formula (I), X1 and X2 are hydrogen, R1 is hydrogen, R2 is hydrogen, A is -CH2CH(R 10 )-, and R 10 is a substituted aryl group.
[0144] In some embodiments of Formula (I), X1 is hydrogen, X2 is hydroxy, R1 is alkyl (e.g., methyl), R2 is alkyl (e.g., methyl), A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0145] In some embodiments of Formula (I), X1 and X2 are hydrogen, R1 is alkyl (eg, methyl), R2 is hydrogen, A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0146] Isoquinoline compounds useful in the compositions and methods described herein include compounds of formula (Ia) or pharmaceutically acceptable salts thereof having tautomeric forms (also shown here for clarity):
[0147]
[0148] in:
[0149] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms; and
[0150] R 10 Selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl and heterocyclyl, any of which may be optionally substituted.
[0151] In some embodiments, R 10 is aryl (eg, phenyl). 10 is heteroaryl (eg, thienyl). In some embodiments, R1 and R2 are independently selected from hydrogen and methyl, or R1 and R2 together with the nitrogen to which they are attached form a heterocyclyl ring (eg, pyrrolidone or piperidine).
[0152] Isoquinoline compounds useful in the compositions and methods described herein include compounds of formula (Ib) or pharmaceutically acceptable salts thereof:
[0153]
[0154] in:
[0155] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms; and
[0156] R 10 Selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl and heterocyclyl, any of which may be optionally substituted.
[0157] In some embodiments, R 10 is aryl (eg, phenyl). 10 is –CH2-OC(O)-R a Substituted aryl (eg, phenyl), wherein R a is an optionally substituted aryl group (eg, phenyl, such as 2,4-dimethylphenyl). 10 is optionally substituted phenyl (e.g., 4-chlorophenyl). 10 is –CH2-OC(O)-NH-R b Substituted aryl (eg, phenyl), wherein R b is optionally substituted aryl (eg phenyl, such as 2-chlorophenyl or 4-chlorophenyl or 4-methoxyphenyl), or R b is an optionally substituted alkyl group (e.g., C 1-4In some embodiments, R1 and R2 are independently selected from hydrogen and methyl, or R1 and R2 together with the nitrogen to which they are attached form a heterocyclyl ring (eg, pyrrolidone or piperidine).
[0158] In an embodiment, the compound of formula (I) may be selected from:
[0159] (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide;
[0160] (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide;
[0161] (S)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide;
[0162] (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate;
[0163] (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate; and
[0164] (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate,
[0165] (rac)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propionamide,
[0166] (R)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide,
[0167] (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide,
[0168] or a pharmaceutically acceptable salt thereof.
[0169] The compounds of formula (I) can be synthesized by methods known in the art. For example, the compounds can be synthesized using the methods described in US Patent Publication No. 2009 / 0186917, which is incorporated herein by reference in its entirety.
[0170] Also disclosed herein are compounds wherein the isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog. Such compounds include compounds of formula (II) or pharmaceutically acceptable salts thereof:
[0171]
[0172] in:
[0173] Y is selected from alkylene, aryl, heteroaryl, cycloalkyl and heterocyclyl, any of which may be optionally substituted;
[0174] B is selected from -NR1R2, -CH2NR1R2, -CH(R 10 )R2、-CCH3(R 10 )R2, -NHCH(R 10 )R2, -N(CH3)R2, -CH2CH2R2, -CH(R 10 )CH2R2 and -CH2CH(R 10 )R2;
[0175] R1, R2 and R 10 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, any of which may be optionally substituted;
[0176] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0177] PG is the acyl group of a prostaglandin or a prostaglandin analog.
[0178] "The acyl group of a prostaglandin or prostaglandin analog" refers to a prostaglandin or prostaglandin analog with -C(O)- at the C1 position. For example, the acyl group of latanoprost, bimatoprost, and travoprost is shown below:
[0179]
[0180]
[0181] In some embodiments of Formula (II), X1 and X2 are hydrogen, B is -CH2NR1R2, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), and PG is an acyl group of latanoprost.
[0182] In some embodiments of Formula (II), X1 and X2 are hydrogen, B is -CH2NR1R2, R1 and R2 are hydrogen, and PG is an acyl group of latanoprost.
[0183] In some embodiments of Formula (II), X1 is hydrogen, X2 is hydroxy, B is -CH2NR1R2, R1 and R2 are hydrogen, and PG is an acyl group of latanoprost.
[0184] In some embodiments of Formula (II), X1 is hydrogen, X2 is hydroxy, B is -NR1R2, R1 is hydrogen, R2 is hydrogen, and PG is an acyl group of travoprost.
[0185] In some embodiments of Formula (II), X1 is hydrogen, X2 is hydroxy, B is -NR1R2, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), and PG is an acyl group of latanoprost.
[0186] In some embodiments of Formula (II), X1 and X2 are hydrogen, B is -CH2NR1R2, R1 is hydrogen, R2 is hydrogen, and PG is an acyl group of travoprost.
[0187] In some embodiments of formula (II), X1 and X2 are hydrogen, B is -CH2NR1R2, R1 is hydrogen, R2 is hydrogen, and PG is the acyl group of bimatoprost.
[0188] In some embodiments of Formula (II), PG is latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, latanoprostene bunod, unoprostone, PGF 2α or the acyl group of fluprostenol.
[0189] Formula (II) compounds can be synthesized according to methods similar to those shown in Scheme 1, in which each R is independently a protecting group. Those skilled in the art will recognize that known methods can be used to prepare the initial protected prostaglandin free acid and isoquinoline; for example, see Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rd Edition; John Wiley and Sons, 1999). Step (a) can be carried out in the presence of a suitable coupling agent (e.g., carbodiimide) in a suitable solvent. After coupling in step (a), the product can be deprotonated in step (b) using a method for the protecting group used. It should be noted that although Scheme 1 illustrates the coupling of latanoprost free acid and a specific isoquinoline compound, those skilled in the art will recognize that such a general synthesis scheme can be used for any prostaglandin free acid and isoquinoline compounds with suitable reactive functional groups (e.g., hydroxyl, amine, etc.). The specific synthesis includes the protection and deprotonation steps described in the embodiment.
[0190] Solution 1
[0191]
[0192] Also disclosed herein are compounds wherein the isoquinoline compound and the prostaglandin or prostaglandin analog form a salt together. Such compounds include compounds of formula (III):
[0193] Compounds useful in the compositions and methods described herein also include isoquinoline compounds and salts of prostaglandin free acids. Such compounds include compounds of formula (III):
[0194]
[0195] in:
[0196] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0197] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0198] Each R 10 independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted;
[0199] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0200] It is the deprotonated free acid of prostaglandin or prostaglandin analog.
[0201] "The deprotonated free acid of a prostaglandin or prostaglandin analog" refers to a prostaglandin or prostaglandin analog wherein the C1 position has the group -C(O)O-. For example, the deprotonated free acids of latanoprost, bimatoprost, and travoprost are shown below:
[0202]
[0203] In some embodiments of formula (III), X1 is hydrogen, X2 is hydroxy, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), A is -CH (R 10 )-, and R 10is an aryl group (eg, phenyl).
[0204] In some embodiments of formula (III), X1 is hydrogen, X2 is hydroxy, R1 and R2 are taken together to form a heterocyclyl ring, and A is -CH(R 10 )-, and R 10 It is an alkyl group.
[0205] In some embodiments of formula (III), X1 and X2 are hydrogen, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0206] In some embodiments of formula (III), X1 and X2 are hydrogen, R1 is hydrogen, R2 is hydrogen, A is -CH2CH(R 10 )-, and R 10 is a substituted aryl group.
[0207] In some embodiments of formula (III), X1 is hydrogen, X2 is hydroxy, R1 is alkyl (eg, methyl), R2 is alkyl (eg, methyl), A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0208] In some embodiments of formula (III), X1 and X2 are hydrogen, R1 is alkyl (eg, methyl), R2 is hydrogen, A is -CH (R 10 )-, and R 10 is a heteroaryl group (eg, thienyl).
[0209] In some embodiments of Formula (III), is the deprotonated free acid of latanoprost, bimatoprost, travoprost, tafluprost, AR-102, latanoprostene bunod or unoprostone. In some embodiments of formula (III), Cloprostenol, 13,14-dihydrocloprostenol, PGE1, PGF 1α 、PGF 2α 、PGF 3α or the deprotonated form of fluprostenol.
[0210] The compound of formula (III) can be synthesized by mixing a prostaglandin free acid and an isoquinoline compound in, for example, a suitable solvent. The starting materials can be mixed in a ratio of about 1:1. If necessary, the mixture can be heated to promote the dissolution of the starting materials. The solvent can then be removed to obtain a salt compound.
[0211] Prostaglandins and prostaglandin analogs
[0212] The compositions described herein may comprise a prostaglandin or a prostaglandin analog.
[0213] In some embodiments, the prostaglandin or prostaglandin analog may comprise a compound of formula (IV) or an optical isomer, diastereomer, or enantiomer thereof:
[0214]
[0215] in:
[0216] Dashed lines independently indicate the presence or absence of a bond;
[0217] A and B are independently -(CR a R b ) n -, where each R a and R b are independently hydrogen or C1-C6 alkyl, and n is 0, 1, 2, 3 or 4;
[0218] R1 is -C(O)OR c ,-CONHR d , -C(O)NHOH, -CH2OH, -S(O)2R e or -C(O)NHS(O)2R f ;
[0219] R2 is hydrogen or C1-C6 alkyl;
[0220] R3, R 4 and R 5 are independently selected from hydrogen and alcohol protecting groups;
[0221] Y is a bond, -O-, -S-, -S(O), -SO2-, -C(R g )2-、-CR h =CR i -、-NR j -or-C=C-;
[0222] Z is hydrogen, cycloalkyl, heterocyclyl, aryl or heteroaryl;
[0223] R c is selected from hydrogen, C1-C6 alkyl, C1-C6 heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl;
[0224] R d , R e and R f independently selected from C1-C6 alkyl, heteroalkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl;
[0225] Rg , R h and R i independently selected from hydrogen, C1-C6 alkyl, alkyl and hydroxy; and
[0226] R j It is hydrogen or C1-C6 alkyl.
[0227] Suitably, no carbon atom in the compound of formula (IV) is bonded to more than 2 heteroatoms unless the 2 or more heteroatoms are members of a heteroaromatic ring system.
[0228] In formula (IV), the relative stereochemistry at C8, C9, and C12 is as indicated. That is, the bond between C7 and C8 is in the alpha orientation, the alcohol of C9 (protected or unprotected) is in the alpha orientation, and the bond between C12 and C13 is in the beta orientation. The present invention also includes optical isomers, diastereomers, and enantiomers of the above structures. At all stereocenters where stereochemistry is not defined (e.g., C11 and C15), diastereomers are contemplated. In some embodiments, the stereochemistry of all such stereocenters of the present invention mimics the naturally occurring PGF 2α .
[0229] In some embodiments, Q1 is H or an alcohol protecting group, and Q2 and Q3 are alcohol protecting groups. In other embodiments, Q1, Q2 and Q3 are all alcohol protecting groups, which may be different alcohol protecting groups or the same alcohol protecting group.
[0230] Exemplary prostaglandins and prostaglandin analogs include latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol and its esters, 13,14-dihydrocloprostenol and its esters, latanoprostene bunod, unoprostone, PGE1 and its esters, PGF 1α Its esters, PGF 2α Its esters, PGF 3α and its esters and fluprostenol and its esters.
[0231] In some embodiments, a pharmaceutically acceptable salt of a prostaglandin or prostaglandin analog is used. For example, the salt may be an amino acid salt of a prostaglandin, such as arginine. In some embodiments, the prostaglandin or prostaglandin analog may be latanoprost arginine salt.
[0232] Other prostaglandins and related compounds suitable for use in the compositions of the present disclosure include, but are not limited to, those appearing in the following patents and patent applications, which are incorporated herein by reference.
[0233] 1. 5-Thia-omega substituted phenyl-prostaglandin E derivatives, process for producing the same and drugs containing the same as the active ingredient. WO 00 / 3980.
[0234] 2.Aromatic C 16 -C 20 -substituted tetrahydro prostaglandins useful as FPagonists 16 -C 20 -substituted tetrahydroprostaglandins) WO 99 / 12895; US5977173, Nov. 2, 1999.
[0235] 3. Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FPagonists 16 -C 20 -substituted tetrahydroprostaglandins) WO 99 / 12898.
[0236] 4. Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FPagonists 16 -C 20 -substituted tetrahydroprostaglandins). WO 99 / 12896, US6048895Apr.11,2000.
[0237] 5. Prostaglandins of the F series (prostaglandins of the F series) US 5770759.Jun.231998.
[0238] 6. EP2-receptor agonists as neuroprotective agents for the eye. WO 99 / 26629.
[0239] 7. Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension. US6030999, Feb.29 2000.
[0240] 8. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents WO 99 / 25358; US 6037364 Mar. 14 2000.
[0241] 9. Use of cloprostenol and fluoprostenol analogues to treat glaucoma and ocular hypertension, US5889052, Mar.30 1999.
[0242] 10. Cis-delta-4-analogs of prostaglandins as ocular hypotensives. WO 98 / 21182; US 5994397 Nov. 30, 1999.
[0243] 11. Tetrahydrofuran analogs of prostaglandins as ocular hypotensives. WO 98 / 57930; US-6,025,392 Mar. 14, 2000.
[0244] 12. Conformationally rigid aryl-or heteroaryl prostaglandins for use in glaucoma therapy. WO 98 / 21180.
[0245] 13. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives WO 98 / 57930.
[0246] 14. 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension WO 99 / 32441.
[0247] 15. 13-Thia prostaglandins for use in glaucoma therapy WO 98 / 39293.
[0248] 16. 15-Ketal prostaglandins for the treatment of glaucoma or ocular hypertension (15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension) WO98 / 20881.
[0249] 17. 9-Oxa prostaglandin analogs as ocular hypotensives. WO 98 / 57942.
[0250] 18. 15-Fluoro prostaglandins as ocular hypotensives WO 98 / 21181.
[0251] 19. 11-Halo prostaglandins for the treatment of glaucoma or ocular hypertension WO 98 / 20880.
[0252] 20. Use of 9-deoxy prostaglandin derivatives to treat glaucoma WO 96 / 10407.
[0253] 21. Prostaglandin product WO 00 / 3736.
[0254] 22. Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives WO 97 / 23223.
[0255] 23. EP2-receptor agonists as agents for lowering intraocular pressure WO 95 / 19964.
[0256] 24. Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma. WO 99 / 02165.
[0257] 25. 8-Iso prostaglandins for glaucoma therapy WO 98 / 50024; US 6037368 Mar.14 2000.
[0258] 26. Fluorinated prostaglandin derivatives and medicines WO 98 / 12175.
[0259] Isomers
[0260] The compounds described herein (e.g., compounds of Formula (I), (Ia), (Ib), (II), (III), and (IV)) may exist in one or more specific geometric, optical, enantiomeric, diastereomeric, epimeric, rotameric, stereoisomeric, tautomeric, conformational, or anomeric forms, including, but not limited to, cis and trans, E- The isomers of the invention are hereinafter collectively referred to as "isomers" (or "isomer forms"), such as keto-, alcohol- and enol-forms, cis-, anti-, para- and syn-forms, boat-, chair-, twist-, envelope- and half-chair-forms, and combinations thereof.
[0261] In one embodiment, the compounds described herein can be enantiomerically enriched isomers of the stereoisomers described herein. For example, the compounds can have an enantiomeric excess of at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%. As used herein, a reference isomer refers to either of a pair of compounds whose molecular structures have a mirror image relationship to each other.
[0262] In one embodiment, the preparations of compounds disclosed herein are enriched in an isomer of a compound having a selected stereochemistry, e.g., R or S corresponding to a selected stereocenter. For example, the compound has a purity appropriate to at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of a compound having a selected stereochemistry at a selected stereocenter.
[0263] In one embodiment, the compositions described herein include preparations of compounds disclosed herein that are enriched in one or more structures having a selected stereochemistry (e.g., R or S) at a selected stereocenter. Exemplary R / S configurations can be those provided in the embodiments described herein.
[0264] As used herein, "enriched preparations" are enriched in the selected configuration of one, two, three or more selected centers in the subject compound. Exemplary selected stereocenters and exemplary stereo configurations thereof can be selected from those provided herein, such as those provided in the embodiments described herein. So-called enrichment means that, for example, at least 60% of the compound molecules in the preparation have the stereochemistry of the selected stereocenter. In one embodiment, it is at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99%. Unless otherwise indicated, enrichment refers to the level of the subject molecule, and does not mean method limitation.
[0265] Compounds can be prepared in racemic form, or prepared as individual enantiomers or diastereomers by stereoselective synthesis or by resolution. For example, compounds can be resolved into their constituent enantiomers or diastereomers by standard techniques, such as by forming a stereoisomer pair with an optically active base, followed by fractional crystallization and regeneration of the free acid. Compounds can also be resolved by forming stereoisomer esters or amides, followed by chromatographic separation and removal of chiral by-products. Alternatively, chiral HPLC columns can be used to resolve compounds. Enantiomers can also be obtained from kinetic resolution of the racemate of the corresponding ester using lipase.
[0266] In addition to the tautomers discussed below, structural isomers (i.e., isomers whose difference lies in the connection between atoms rather than only the spatial atomic position) are specifically excluded from the term "isomer" as used herein. For example, a reference to methoxy-OCH3 should not be interpreted as a reference to its structural isomer hydroxymethyl-CH2OH. Similarly, a reference to o-chlorophenyl should not be interpreted as a reference to its structural isomer m-chlorophenyl. However, a reference to a class of structures may appropriately include structural isomeric forms falling within that class (e.g., C3-alkyl or propyl includes n-propyl and isopropyl, C4-alkyl or butyl includes n-, iso-, sec-, and tert-butyl, and methoxyphenyl includes o-, m-, and p-methoxyphenyl).
[0267] The above exclusion does not relate to tautomeric forms, such as keto, alcohol and enol, such as in the following tautomeric pairs: keto / alcohol, imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thione / enethiol, N-nitroso / hydroxyazo and nitro / isonitro.
[0268] Note that compounds having one or more isotopic substitutions are expressly included in the term "isomers". For example, H may be in geometric isotopic forms including 1 H. 2 H(D) and 3 H(T); C can be in geometric isotopic forms, including 12 C. 13 C and 14C; O can be in geometric isotopic forms, including 16 O and 18 O; etc.
[0269] Salt
[0270] The compounds described herein may be in the form of salts, such as pharmaceutically acceptable salts. The term "pharmaceutically acceptable salts" includes salts of active compounds prepared using relatively nontoxic acids or bases, depending on the specific substituents present on the compounds described herein. The neutral form of the compound can be regenerated by contacting the salt with a base or acid and separating the parent compound in a conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but in other aspects, the salt is equivalent to the parent form of the compound for the purposes of the present disclosure. Examples of pharmaceutically acceptable salts are described in Berge et al., 1977, "Pharmaceutically Acceptable Salts." J. Pharm. Sci. Vol. 66, pp. 1-19.
[0271] For example, if the compound is anionic, or has a functional group that can be anionic (e.g., -COOH can be -COO - ), then a suitable cation may be used to form a salt. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na + and K + ; Alkaline earth metal cations, such as Ca 2+ and Mg 2+ ; and other cations. Examples of suitable organic cations include, but are not limited to, ammonium ions (i.e., NH4 + ) and substituted ammonium ions (e.g., NH3R1 + NH2R2 + 、NHR3 + NR4 + Some examples of suitable substituted ammonium ions are those obtained from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, and amino acids (e.g., lysine and arginine).
[0272] If the compound is cationic, or has a functional group that can be cationic (e.g., -NH2 can be -NH3 + ), then, a suitable anion can be used to form a salt. Examples of suitable inorganic anions include, but are not limited to, those obtained from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.
[0273] Examples of suitable organic anions include, but are not limited to, those obtained from the following organic acids: 2-acetoxybenzoic acid, acetic acid, ascorbic acid, aspartic acid, benzoic acid, camphorsulfonic acid, cinnamic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glutamic acid, glycolic acid, hydroxymaleic acid, hydroxynaphthalenecarboxylic acid, isethionic acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, methanesulfonic acid, mucic acid, oleic acid, oxalic acid, palmitic acid, pamoic acid, pantothenic acid, phenylacetic acid, benzenesulfonic acid, propionic acid, pyruvic acid, salicylic acid, stearic acid, succinic acid, sulfanilic acid, tartaric acid, p-toluenesulfonic acid, and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those obtained from the following polymeric acids: tannic acid, carboxymethylcellulose.
[0274] Unless otherwise indicated, a reference to a particular compound also includes its salt forms.
[0275] Chemical protection form
[0276] Chemically protected active compounds can be prepared, purified and / or treated conveniently or desirably. The term "chemically protected form" is used herein in the conventional chemical sense, and relates to a compound in which one or more reactive functional groups are protected from undesirable chemical reactions under specified conditions (e.g., pH, temperature, irradiation, solvent, etc.). In fact, a functional group is reversibly rendered non-reactive under specified conditions using known chemical methods, otherwise the functional group would be reactive. In a chemically protected form, one or more reactive functional groups are in the form of a protected group or a protecting group (also referred to as a masked group or a masking group or a capped group or an end-capping group). By protecting the reactive functional group, reactions involving other unprotected reactive functional groups can be carried out without affecting the protected group; the protecting group can be removed, usually in a subsequent step, without substantially affecting the remainder of the molecule. For example, see Protective Groups in Organic Synthesis (T. Green and P. Wuts; 3rd edition; John Wiley and Sons, 1999). Unless otherwise indicated, a reference to a particular compound also includes its chemically protected forms.
[0277] Many such "protection", "capping" or "masking" methods are widely used and well known in organic synthesis. For example, a compound having two non-equivalent reactive functional groups, both reactive under specified conditions, can be derivatized to render one functional group "protected" and therefore unreactive under specified conditions; the compound thus protected can be used as a reactant, which actually has only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group can be "deprotected" to restore its original functionality.
[0278] The hydroxyl group may be protected as an ether (-OR) or an ester (-OC(O)R), for example, tert-butyl ether, benzyl, diphenylmethyl (diphenylmethyl) or triphenylmethyl (triphenylmethyl) ether, trimethylsilyl or tert-butyldimethylsilyl ether, or an acetyl ester (-OC(O)CH3, -OAc).
[0279] The aldehyde or ketone group can be protected as an acetal (RCH(OR)2) or ketal (R2C(OR)2), respectively, wherein the carbonyl R2C=O) is converted into a diether (R2C(OR)2), for example by reaction with a primary alcohol. The aldehyde or ketone group can be regenerated by hydrolysis using a large excess of water in the presence of an acid.
[0280] Amine groups can be protected, for example, as amides (-NRC(O)R) or aminoesters (-NRC(O)OR), for example: methylamide (-NHC(O)CH3), benzyloxyamide (-NHC(O)OCH2C6H5, -NH-Cbz), tert-butoxyamide (-NHC(O)OC(CH3)3, -NH-Boc), 2-biphenyl-2-propoxyamide (-NHCO(O)C(CH3)2C6H4C6H5, -NH- Bpoc), 9-fluorenylmethoxyamide (-NH-Fmoc), 6-nitroveratryloxyamide (-NH-Nvoc), 2-trimethylsilylethyloxyamide (-NH-Teoc), 2,2,2-trichloroethyloxyamide (-NH-Troc), allyloxyamide (-NH-Alloc), 2(-phenylsulfonyl)ethyloxyamide (-NH-Psec); or, where appropriate (e.g., cyclic amines), nitrooxy
[0281] The carboxylic acid group can be protected as an ester, for example, an alkyl ester (e.g., methyl ester, tert-butyl ester), a haloalkyl ester (e.g., a haloalkyl ester), a trialkylsilylalkyl ester, or an arylalkyl ester (e.g., benzyl ester, nitrobenzyl ester), or an amide, such as methyl amide.
[0282] The thiol group can be protected as a thioether (-SR), such as benzyl thioether, acetamidomethyl ether (-S-CH2NHC(O)CH3).
[0283] Prodrugs and other modifications
[0284] In addition to salt forms, the present invention can also provide compounds in the form of prodrugs. Prodrugs of compounds described herein are those compounds that are susceptible to chemical changes under physiological conditions to provide compounds described herein. Prodrugs can be converted into compounds of the present invention by chemical or biochemical methods in in vitro experiments. For example, when placed in a transdermal patch library with or without a suitable enzyme or chemical reagent, prodrugs can be slowly converted into compounds of the present invention.
[0285] The compounds described herein may also be modified by the addition of appropriate functionality to enhance selective biological properties. Such modifications are known in the art and include those that increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), those that increase oral availability, those that improve solubility to allow injection, those that alter metabolism, and / or those that alter excretion rates. Examples of these modifications include, but are not limited to, esterification with polyethylene glycol, derivatization with pivalate or fatty acid substituents, conversion to carbamates, hydroxylation of aromatic rings, and heteroatom substitution in aromatic rings.
[0286] Composition
[0287] In one aspect, the present disclosure provides a composition comprising a compound of formula (I) as described herein (e.g., a compound of formula (I), a compound of formula (Ia), or a compound of formula (Ib)) and a prostaglandin or a prostaglandin analog (e.g., a compound of formula (IV)). In another aspect, the present disclosure may provide a composition comprising 2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride (e.g., a racemic compound or (R) or (S) enantiomer) and a hydroxyl group selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α In another aspect, the present disclosure may provide a composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate (e.g., a racemic compound or (R) or (S) enantiomer) and a compound selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3αIn another aspect, the present disclosure may provide a composition comprising 3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propionamide (e.g., a racemic compound or (R) or (S) enantiomer) and a compound selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α In another aspect, the present disclosure provides a composition comprising a compound of formula (II) as described herein. In another aspect, the present disclosure provides a composition comprising a compound of formula (III) as described herein.
[0288] The compositions of the present disclosure may include a safe and effective amount of the subject compound. "Safe and effective amount" as used herein means an amount of the compound sufficient to induce a significant positive change in the condition to be treated within the scope of reasonable medical judgment, yet low enough to avoid serious side effects (at a reasonable benefit / risk ratio). The safe and effective amount of the compound will vary with the specific condition to be treated, the age and physical condition of the patient to be treated, the severity of the condition, the duration of treatment, the nature of concurrent treatments, the specific pharmaceutically acceptable carrier used, and similar factors within the knowledge and experience of the attending physician.
[0289] In embodiments, the composition may comprise a compound of Formula (I), (la), (lb), (II), or (III) in an amount of about 0.001% to about 2.0% w / v, e.g., about 0.01% to about 1.0% w / v. In embodiments, the compound of Formula (I), (Ia), (Ib), (II) or (III) can be included in the composition in an amount of less than about 0.0025%, less than about 0.010%, less than about 0.015%, less than about 0.025%, less than about 0.05%, less than about 0.080%, less than about 0.10%, less than about 0.20%, less than about 0.40%, less than about 0.60%, less than about 0.80%, less than about 0.10%, less than about 0.5%, less than about 0.7%, less than about 1.0%, less than about 1.2%, less than about 1.4%, less than about 1.5%, less than about 1.6%, less than about 1.8%, less than about 2.0%, at least about 0.0025%, at least about 0.0 ... About 0.010%, at least about 0.015%, at least about 0.020%, at least about 0.05%, at least about 0.075%, at least about 0.10%, at least about 0.20%, at least about 0.40%, at least about 0.60%, at least about 0.80, at least about 1.0%, at least about 1.2%, at least about 1.4%, at least about 1.6%, at least about 1.8%, at least about 2.0, about 0.0025%, about 0.010%, about 0.015%, about 0.03%, about 0.05%, about 0.10%, about 0.20%, about 0.40%, about 0.60%, about 0.80%, about 1.0%, about 1.2%, about 1.4%, about 1.6%, about 1.8% or about 2.0%.
[0290] In embodiments, the composition may comprise a prostaglandin or a prostaglandin analog (e.g., a compound of formula (IV) or latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-cloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3αisopropyl ester or fluprostenol isopropyl ester) in an amount of about 0.0001% to about 0.5% w / v, such as about 0.0005% to about 0.1% w / v or about 0.001% to about 0.05%. In embodiments, the prostaglandin or prostaglandin analog may be included in the composition in an amount of about 0.001%, about 0.002%, about 0.003%, about 0.004%, about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.010%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, about 0.015%, about 0.016%, about 0.017%, about 0.018%, about 0.019%, about 0.020%, about 0.021%, about 0.022%, about 0.023% , about 0.024%, about 0.025%, about 0.026%, about 0.027%, about 0.028%, about 0.029%, about 0.030%, about 0.031%, about 0.032%, about 0.033%, about 0.034%, about 0.035%, about 0.036%, about 0.037%, about 0.038%, about 0.039%, about 0.040%, about 0.041%, about 0.042%, about 0.043%, about 0.044%, about 0.045%, about 0.046%, about 0.047%, about 0.048%, about 0.049% or about 0.050%.
[0291] Additional components
[0292] The compositions of the present disclosure may further comprise one or more pharmaceutically acceptable excipients. For example, the compositions may comprise additional pharmaceutically acceptable components such as buffers, tonicity agents, chelating agents, sugars or sugar alcohols, viscosity enhancers, and surfactants.
[0293] Buffers can include, for example, phosphate buffers, boric acid buffers, citric acid buffers, maleic acid buffers, tartaric acid buffers, acetic acid buffers, tris (hydroxymethyl) aminomethane (TRIS), amino acid buffers (e.g., glycine), combination buffers (e.g., boric acid / phosphate buffers, citric acid / phosphate buffers), etc. In embodiments, the composition can include a buffer sufficient to provide a buffering capacity for the composition. Although other components of the composition have other functions, they may also affect the buffering capacity. For example, ethylenediaminetetraacetic acid (EDTA), which is commonly used as a chelating agent, can have an effect on the buffering capacity of the solution.
[0294] The composition may include one or more tonicity agents so that the composition can be isotonic with body fluids. The tonicity agent may be nonionic or ionic. Nonionic tonicity agents include sugars, sugar alcohols and other polyols, glycols, such as glycerol, mannitol, erythritol and sugars such as glucose. Other nonionic tonicity agents may also be used, including, for example, polyethylene glycol, propylene glycol, which may also be used as a co-solvent. The tonicity agent may also be an ionic agent, such as sodium chloride, potassium chloride, a balanced salt solution, sodium phosphate or sodium citrate. For example, a nonionic tonicity agent may be included in the composition in the following amounts: about 0.10-about 20%, about 1.0-about 10% or about 2.0-about 6.0%. An ionic tonicity agent may be included in the composition in the following amounts: about 0.10%-about 2.5%, about 0.25%-about 2.0% or about 0.50%-about 1.0% w / v.
[0295] The composition may also include one or more chelating agents or sequestrants. A large number of organic acids, amines or compounds containing acid groups and amine functional groups can be used as chelating agents. For example, nitrilotriacetic acid, diethylenetriaminepentaacetic acid, hydroxyethylethylenediaminetriacetic acid, 1,2-diaminocyclohexanetetraacetic acid, hydroxyethylaminodiacetic acid, ethylenediaminetetraacetic acid and its salts, polyphosphoric acid, citric acid and its salts, tartaric acid and its salts, etc. and mixtures thereof can be used as chelating agents. Ethylenediaminetetraacetic acid (EDTA) and its alkali metal salts are suitable chelating agents, such as the disodium salt of EDTA (also known as disodium edetate). In embodiments, the chelating agent may be included in the composition in the following amounts: about 0.001%-about 0.25% w / v, about 0.005%-about 0.15% w / v or about 0.01%-about 0.1% w / v. In embodiments, the composition may include a chelating agent in an amount effective to enhance the effectiveness of the antimicrobial component and / or to form a complex with a metal ion.
[0296] The composition may further include one or more preservatives. Suitable preservatives include, but are not limited to, sodium bisulfite, sodium bisulfate, sodium thiosulfate, ascorbate, benzalkonium chloride, benzammonium bromide, chlorobutanol, thimerosal, phenylmercuric acetate, phenylmercuric borate, phenylmercuric nitrate, parabens (e.g., methylparaben, ethylparaben and propylparaben), polyvinyl alcohol, benzyl alcohol, phenylethyl alcohol, sodium benzoate, sorbic acid, polyquaternium-1, etc. and mixtures thereof. In embodiments, the composition may include a preservative in the following amounts: 0.001-about 1% or about 0.005-about 0.10% w / v. In embodiments, the composition may include a preservative that effectively inhibits microbial growth or composition contamination.
[0297] The composition may further comprise a surfactant. Surfactants include nonionic, anionic, amphoteric and zwitterionic surfactants. Exemplary surfactants include, but are not limited to, sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene stearates (e.g., polyoxyethylene (40) stearate, such as Myrj TM -52), poloxamers, dexchlorpheniramine maleate (polaxamines), sorbitan fatty acid esters, polyethylene glycols (e.g., PEG-400), polyethoxylated alcohols, polyethoxylated castor oils (e.g., PEG-40 hydrogenated castor oil, e.g. RH 40), docusate sodium, quaternary ammonium compounds, medium-chain and long-chain fatty acids, sugar esters of fatty acids and glycerides of fatty acids, lecithin, polysorbate 80, polyphospholipids and sodium lauryl sulfate. Suitable surfactants include those disclosed in the following materials: CTFA Cosmetic Ingredient Handbook, 1992, pp.587-592; Remington's Pharmaceutical Sciences, 15th Ed. 1975, pp.335-337; and McCutcheon's Volume 1, Emulsifiers & Detergents, 1994, North American Edition, pp.236-239. The surfactant can be included in the composition in the following amounts: about 0.01% to about 5% or about 0.1% to about 2% w / v.
[0298] The composition may also include a viscosity increasing agent, which may increase the residence time of the composition on the ocular surface. Exemplary viscosity increasing agents include, but are not limited to, water-soluble natural gums, cellulose-derived polymers, and the like. Suitable natural gums include guar gum, tragacanth gum, and the like. Suitable cellulose-derived viscosity inducing components include cellulose-derived polymers, such as sodium carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, and the like. The viscosity increasing agent may be included in the composition in the following amounts: about 0.01% to about 5% or about 0.1% to about 3% w / v.
[0299] The compositions described herein may also include a solvent. The compositions are generally aqueous, but may also include an optional co-solvent. Suitable co-solvents include, but are not limited to, alcohols (e.g., ethanol and isopropanol), ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulfoxide, dimethylformamide, castor oil, and combinations thereof. In addition to the compound of formula (I) or (II), prostaglandins, and other optional components, the remainder of the composition may include a solvent.
[0300] pH
[0301] The pH of the composition can affect the stability of the compound and its efficacy. For example, a higher pH may cause the compound of formula (I) to decompose, while a lower pH may irritate the eyes. In embodiments, the pH may be from about 4.0 to about 7.0 or from about 5.0 to about 6.0. In embodiments, the composition may have a pH of at least about 5.0, at least about 5.5, at least about 6.0, at least about 6.5, at least about 7.0, less than about 5.0, less than about 5.5, less than about 6.0, less than about 6.5, less than about 7.0, about 5.0, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, or about 6.0.
[0302] If necessary, the pH of the composition can be adjusted using an acid or base. Any acid or base compatible with the composition components can be used. Exemplary acids include hydrochloric acid, citric acid, gluconic acid, lactic acid, acetic acid, and glycolic acid. Exemplary bases include sodium hydroxide, potassium hydroxide, and triethanolamine.
[0303] Method for preparing the composition
[0304] The composition can be prepared using standard methods. In an embodiment, the composition components can be mixed in water (e.g., purified water) under stirring, and then the pH is adjusted to a suitable final pH. The techniques for preparing the composition are generally found in "Remington's Pharmaceutical Sciences", (Meade Publishing Co., Easton, Pa.).
[0305] When preparing the composition, the components should be selected to optimize solubility, stability and compatibility. Typically, the composition should be sterile and stable under the conditions of manufacture and storage. The composition can be sterilized by filtering the composition through a sterilizing grade filter (e.g., a filter with a nominal pore size of 0.22 microns).
[0306] Methods for evaluating compositions
[0307] The stability of the composition can be evaluated using established procedures. For example, the composition can be subjected to accelerated stability testing. For example, the composition is stored at 40°C for at least 1 month, 3 months, or 6 months before evaluation, and they remain stable and do not undergo precipitation. The active ingredient (e.g., 6- or 7-aminoisoquinoline compound) should not react or decompose with other formulation components. Methods for evaluating such compounds include, for example, high performance liquid chromatography (HPLC) or determining optical rotation (e.g., determining whether the compound has begun to racemize).
[0308] For parenteral / ophthalmic products, the USP preservative effectiveness test can also be used to evaluate the composition. In this test, known to those skilled in the art, five indicator organisms are used for the purpose of attacking the preservative system of the product. Three of the five USP indicator organisms are for bacterial growth: Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. Candida albicans is a representative yeast, while Aspergillus niger is a mold. 1 x 10 5 (100,000)-1x 10 6 (1,000,000) colony forming units (CFU) / mL of product are inoculated (contaminated) with a large number of organisms. At different intervals depending on the category, the composition is tested to determine its ability to control microbial reproduction or destroy microorganisms. The logarithmic reduction is evaluated at each test interval required for the category. According to the test definition, any growth of any indicator microorganism exceeding the specified amount indicates that the preservative in the product is invalid. The composition can also be evaluated using the preservative effectiveness test of the European Pharmacopoeia, which also evaluates the growth of Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans and Aspergillus niger. The composition of the present disclosure will pass at least one of these preservative effectiveness tests.
[0309] Pharmacological activity against glaucoma can be demonstrated using an assay designed to test the ability of the subject compounds to reduce intraocular pressure. Examples of such assays are described in the following paper, incorporated herein by reference: C. Liljebris, G. Selen, B. Resul, J. Sternschantz and U. Hacksell, "Derivatives of 17-Phenyl-18,19,20-trinorprostaglandin F 2α Isopropyl Ester: Potential Anti-glaucoma Agents(17-phenyl-18,19,20-trinorprostaglandin F 2α Isopropyl ester derivatives: potential antiglaucoma agents)", Journal of Medicinal Chemistry, Vol. 38 (2) 1995, pp. 289-304. Additional methods are described in the Examples.
[0310] How to use
[0311] One aspect of the present disclosure relates to a method for treating an ophthalmic condition in a subject in need of treatment, comprising administering to the subject a safe and effective amount of a composition comprising an isoquinoline compound (e.g., a compound of formula (I)) and a prostaglandin or a prostaglandin analog. Another embodiment includes a method for treating an ophthalmic condition in a subject in need of treatment, comprising administering to the subject a safe and effective amount of a composition comprising a compound of formula (II). Another embodiment of the present disclosure includes a method for reducing intraocular pressure, comprising administering to a subject in need thereof a safe and effective amount of a composition comprising an isoquinoline compound (e.g., a compound of formula (I)) and a prostaglandin or a prostaglandin analog. Another embodiment includes a method for reducing intraocular pressure, comprising administering to a subject in need thereof a safe and effective amount of a composition comprising a compound of formula (II).
[0312] The compounds of formula (I) and (II) and compositions comprising them may have kinase inhibitory activity and may therefore be used to affect or inhibit kinase action and treat and / or prevent diseases or conditions affected by kinases. Exemplary kinases that may be affected include, but are not limited to, ROCK-I, ROCK-II, PKA, PKC, CAM kinases, GRK-2, GRK-3, GRK-5, or GRK-6. In a suitable embodiment, the kinase that is inhibited is a Rho-associated protein kinase.
[0313] In an embodiment, the compositions of the present disclosure may be administered topically. Topical compositions that may be topically applied to the eye may be in any form known to those skilled in the art, non-limiting examples of which include drops, sprays, ointments, or sustained-release or non-sustaining-release units placed in the conjunctival sac of the eye or another suitable location.
[0314] Depending on the patient being treated, the condition being treated, the severity of the condition being treated, the route of administration, and the like, the dosage may be varied to achieve the desired effect.
[0315] Administration of a compound or composition described herein can result in a decrease in intraocular pressure (IOP) of at least about 3.0 mmHg, at least about 3.5 mmHg, at least about 4.0 mmHg, at least about 4.5 mmHg, at least about 5.0 mmHg, at least about 5.5 mmHg, at least about 6.0 mmHg, at least about 6.5 mmHg, at least about 7.0 mmHg, at least about 7.5 mmHg, at least about 8.0 mmHg, at least about 8.5 mmHg, at least about 9.0 mmHg, In some embodiments, administration of a composition comprising a compound of formula (I) and a prostaglandin or a prostaglandin analog may reduce intraocular pressure more than either compound alone, or more than the intraocular pressure reduced when both compounds are administered in separate compositions.
[0316] This article also discloses but is not limited to the following embodiments:
[0317] Embodiment 1. A composition comprising:
[0318] a) a compound of formula (I) or a pharmaceutically acceptable salt thereof:
[0319]
[0320] in:
[0321] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0322] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0323] Each R 10 independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted; and
[0324] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0325] b) a prostaglandin or a prostaglandin analog or a pharmaceutically acceptable salt thereof.
[0326] Embodiment 2. The composition of embodiment 1, wherein X1 is hydrogen and X2 is hydroxy.
[0327] Embodiment 3. The composition of any one of Embodiments 1-2, wherein A is -CH(R 10 )-,R 10 is optionally substituted aryl or optionally substituted heteroaryl.
[0328] Embodiment 4. The composition of embodiment 3, wherein R 10 is an unsubstituted monocyclic heteroaryl.
[0329] Embodiment 5. The composition of embodiment 4, wherein R 10 is an unsubstituted thienyl group.
[0330] Embodiment 6. The composition of any one of Embodiments 1-5, wherein R1 and R2 are each independently selected from hydrogen and C1-C4 alkyl.
[0331] Embodiment 7. The composition of any one of Embodiments 1-6, wherein the compound of formula (I) is selected from (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide, (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide and (S)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide and pharmaceutically acceptable salts thereof.
[0332] Embodiment 8. The composition of embodiment 1, wherein X1 is hydrogen and X2 is hydrogen.
[0333] Embodiment 9. The composition of embodiment 8, wherein -CH2CH(R 10 )-,R 10 is a substituted aryl group.
[0334] Embodiment 10. The composition of embodiment 9, wherein R 10 is a substituted phenyl group.
[0335] Embodiment 11. The composition of embodiment 10, wherein R 10 is –CH2-OC(O)-R aSubstituted phenyl, wherein R a is an optionally substituted aryl group.
[0336] Embodiment 12. The composition of embodiment 11, wherein R a It is 2,4-dimethylphenyl.
[0337] Embodiment 13. The composition of Embodiment 9, wherein the substituent is halogen.
[0338] Embodiment 14. The composition of embodiment 9, wherein R 10 It is p-chlorophenyl.
[0339] Embodiment 15. The composition of any one of embodiments 8-12, wherein the compound of formula (I) is selected from (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester, (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester and (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester and pharmaceutically acceptable salts thereof.
[0340] Embodiment 16. The composition of any one of embodiments 8-10, 13 or 14, wherein the compound of formula (I) is selected from (R)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide, (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide, (rac)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide and pharmaceutically acceptable salts thereof.
[0341] Embodiment 17. The composition of any one of embodiments 1-16, wherein the prostaglandin or prostaglandin analog is selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF1 isopropyl ester, PGF2 isopropyl ester, PGF3 isopropyl ester and fluprostenol isopropyl ester.
[0342] Embodiment 18. The composition of any one of embodiments 1-17, wherein the composition further comprises at least one component selected from a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity increasing agent, a sugar or a sugar alcohol, and a surfactant.
[0343] Embodiment 19. A compound of formula (II) or a pharmaceutically acceptable salt thereof:
[0344]
[0345] in:
[0346] Y is selected from alkylene, aryl, heteroaryl, cycloalkyl and heterocyclyl, any of which may be optionally substituted;
[0347] B is selected from -NR1R2, -CH2NR1R2, -CH(R 10 )R2、-CCH3(R 10 )R2, -NHCH(R 10 )R2, -N(CH3)R2, -CH2CH2R2, -CH(R 10 )CH2R2 and -CH2CH(R 10 )R2;
[0348] R1, R2 and R 10 are each independently selected from hydrogen, alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl and heterocycloalkyl, any of which may be optionally substituted;
[0349] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0350] PG is the acyl group of a prostaglandin or a prostaglandin analog.
[0351] Embodiment 20. The compound of Embodiment 19, wherein X1 and X2 are hydrogen and Y is selected from alkylene, aryl, heteroaryl, cycloalkyl and heterocyclyl.
[0352] Embodiment 21. The compound of any one of Embodiments 19-20, wherein B is -NR1R2.
[0353] Embodiment 22. The compound of any one of Embodiments 19-21, wherein R1 and R2 are each independently selected from hydrogen and C1-C4 alkyl.
[0354] Embodiment 23. The compound of any one of embodiments 19-22, wherein the PG acyl group is selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, 13,14-dihydrocloprostenol, latanoprostene bunod, unoprostone, PGF 1α 、PGF 2α 、PGF 3α and the acyl group of fluprostenol.
[0355] Embodiment 24. A composition comprising a compound according to any one of embodiments 19 to 23 and at least one component selected from a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity increasing agent, a sugar or a sugar alcohol, and a surfactant.
[0356] Embodiment 25. Compound of formula (III):
[0357]
[0358] in:
[0359] R1 and R2 are independently selected from hydrogen and C1-C4 alkyl, or R1 and R2 together with the nitrogen atom to which they are attached form a ring of 3, 4, 5, 6, 7 or 8 member atoms;
[0360] A is selected from -CH2NH-, -CH(R 10 )-、-C(CH3)(R 10 )-、-CH2CH2-、-CH(R 10 )CH2-、-CH2CH2CH(R 10 )-、-CH2CH(R 10 )- and -C(CH3)(R 10 )CH2-;
[0361] Each R 10 independently selected from alkyl, alkenyl, alkynyl, amino, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, any of which may be optionally substituted;
[0362] X1 and X2 are independently selected from hydrogen, hydroxy, halogen, alkyl, amino, nitro, cyano, carbonyl, carbonylamino, alkoxy, aryloxy, sulfonyl, sulfonamido, alkylthio, and carboxyl; and
[0363] It is the deprotonated free acid of prostaglandin or prostaglandin analog.
[0364] Embodiment 26. The compound of Embodiment 25 wherein X1 is hydrogen and X2 is hydroxy.
[0365] Embodiment 27. The compound of any one of Embodiments 25-26, wherein A is -CH(R 10 )-,R 10 is optionally substituted aryl or optionally substituted heteroaryl.
[0366] Embodiment 28. The compound of embodiment 27, wherein R 10 is an unsubstituted monocyclic heteroaryl.
[0367] Embodiment 29. The compound of embodiment 28, wherein R10 is an unsubstituted thienyl group.
[0368] Embodiment 30. The compound of any one of Embodiments 25-29, wherein R1 and R2 are each independently selected from hydrogen and C1-C4 alkyl.
[0369] Embodiment 31. The compound of Embodiment 25 wherein X1 is hydrogen and X2 is hydrogen.
[0370] Embodiment 32. The compound of embodiment 31, wherein -CH2CH(R 10 )-, R 10 is a substituted aryl group.
[0371] Embodiment 33. The compound of embodiment 32, wherein R 10 is a substituted phenyl group.
[0372] Embodiment 34. The compound of embodiment 33, wherein R 10 is –CH2-OC(O)-R a Substituted phenyl, wherein R a is an optionally substituted aryl group.
[0373] Embodiment 35. The compound of embodiment 34, wherein R a It is 2,4-dimethylphenyl.
[0374] Embodiment 36. The compound of embodiment 33, wherein R 10 It is a p-substituted phenyl group.
[0375] Embodiment 37. The compound of Embodiment 36, wherein the substituent is halogen.
[0376] Embodiment 38. The compound of embodiment 37, wherein the substituent is chloro.
[0377] Embodiment 39. The compound of any one of embodiments 25-38, wherein Selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol, 13,14-dihydrocloprostenol, latanoprostene bunod, unoprostone, PGE1, PGF 1α 、PGF 2α 、PGF 3α and the deprotonated free acid of fluprostenol.
[0378] Embodiment 40. A composition comprising a compound according to any one of embodiments 25-39 and at least one component selected from a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity increasing agent, a sugar or a sugar alcohol, and a surfactant.
[0379] Embodiment 41. A composition comprising:
[0380] a)(rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0381] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0382] Embodiment 42. A composition comprising:
[0383] a) (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0384] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0385] Embodiment 43. A composition comprising:
[0386] a) (S)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride; and
[0387] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0388] Embodiment 44. A composition comprising:
[0389] a) (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dimethanesulfonate; and
[0390] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0391] Embodiment 45. A composition comprising:
[0392] a) (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0393] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0394] Embodiment 46. A composition comprising:
[0395] a) (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0396] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0397] Embodiment 47. A composition comprising:
[0398] a) (R)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0399] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0400] Embodiment 48. A composition comprising:
[0401] a) (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0402] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0403] Embodiment 49. A composition comprising:
[0404] a)(rac)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide; and
[0405] b) selected from latanoprost, bimatoprost, travoprost, tafluprost, AR-102, cloprostenol isopropyl ester, 13,14-dihydrocloprostenol isopropyl ester, latanoprostene bunod, unoprostone, PGF 1α Isopropyl ester, PGF 2α Isopropyl ester, PGF 3α Prostaglandins of isopropyl ester and fluprostenol isopropyl ester.
[0406] Embodiment 50. The composition of any one of embodiments 41-49, wherein the composition further comprises at least one component selected from a buffer, a chelating agent, a tonicity agent, a preservative, a viscosity increasing agent, a sugar or a sugar alcohol, and a surfactant.
[0407] Embodiment 51. A method of treating an ophthalmic condition in a subject in need of treatment, comprising administering to the subject a compound or composition of any one of Embodiments 1-50.
[0408] Embodiment 52. The method of embodiment 51, wherein the ophthalmic condition is glaucoma.
[0409] Embodiment 53. The method of embodiment 52, wherein the compound or composition is administered topically to the eye of the subject.
[0410] Embodiment 54. A method of reducing intraocular pressure in a subject in need thereof, comprising topically administering to an eye of the subject a compound or composition of any one of Embodiments 1-50.
[0411] Embodiment 55. A compound selected from:
[0412] a) (R)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate;
[0413] b) (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and
[0414] c) (rac)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate.
[0415] The following examples are intended to be illustrative and should be construed as non-limiting.
[0416] Example
[0417] Example 1. Formulations containing travoprost
[0418] The topical pharmaceutical composition for reducing intraocular pressure is prepared by conventional methods and formulated as follows:
[0419]
[0420]
[0421] Formulations 1-3 were prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 or polyoxyethylene (40) hydrogenated castor oil to a labeled 150 milliliter (mL) plastic container. 100 milliliters (mL) of purified water were then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 1.5% benzalkonium chloride, a stock solution of 0.4% travoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added, the solution was stirred for an additional 10 minutes to allow dissolution, and the pH was adjusted to approximately 5.5.
[0422] Formulation 4 was prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 or polyoxyethylene (40) hydrogenated castor oil to a labeled 150-mL plastic container. 100 mL of purified water was then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. (R)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride and travoprost were then added, the solution was stirred for an additional 10 minutes to dissolve, and the pH was adjusted to approximately 5.5.
[0423] Formulation 1 passed the requirements of the United States Pharmacopoeia Preservative Effectiveness Test (USP), the European Pharmacopoeia Preservative Effectiveness Test (EP-A), and the European Pharmacopoeia Preservative Effectiveness Test (EP-B) for Parenteral / Ophthalmic Products.
[0424] Example 2. Formulations containing latanoprost
[0425] The topical pharmaceutical composition for reducing intraocular pressure is prepared by conventional methods and formulated as follows:
[0426]
[0427] Formulations 5 and 6 were prepared by adding sodium dihydrogen phosphate, sodium monohydrogen phosphate, sodium chloride, and EDTA to a labeled 150 milliliter (mL) plastic storage container. 100 milliliters (mL) of purified water were then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. A stock solution of 1.5% benzalkonium chloride and 0.5% latanoprost and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added, the solution was stirred for an additional 10 minutes to dissolve, and the pH was adjusted to approximately 5.5.
[0428]
[0429] Formulations 7 and 8 were prepared by adding boric acid, D-mannitol, and EDTA to a labeled 150 milliliter (mL) plastic container. 100 milliliters (mL) of purified water were then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 1.5% benzalkonium chloride, a stock solution of 0.5% travoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added, the solution was stirred for an additional 10 minutes to allow dissolution, and the pH was adjusted to approximately 5.5.
[0430] Example 3. Preparations containing bimatoprost
[0431] The topical pharmaceutical composition for reducing intraocular pressure is prepared by conventional methods and formulated as follows:
[0432]
[0433] Formulations 9 and 10 were prepared by adding sodium dihydrogen phosphate, sodium monohydrogen phosphate, sodium chloride, and EDTA to a labeled 150 milliliter (mL) plastic storage container. 100 milliliters (mL) of purified water were then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. A 1.5% stock solution of benzalkonium chloride, bimatoprost, and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added, the solution was stirred for an additional 10 minutes to allow dissolution, and the pH was adjusted to approximately 5.5.
[0434] Formulation 11 was prepared by adding boric acid and D-mannitol to a labeled 150 milliliter (mL) plastic storage container. 100 milliliters (mL) of purified water were then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. Bimatoprost and (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride were then added, the solution was stirred for an additional 10 minutes to dissolve, and the pH was adjusted to approximately 5.5.
[0435] Example 4. Exemplary Combination Therapies
[0436] Taiwan macaques (Macaca cyclopis) were used in this study, and animal identification consisted of uniquely numbered tattoos and color-coded cage cards. On the first day of the study, the animals were at least 4 years old and weighed at least 4 kg. A paired study design was used to determine the efficacy and tolerability of ocular hypotensive drugs, in which qdAM was administered to one eye of each monkey for three days (n=6 / group), and the untreated contralateral eye served as an internal control. Each dose was administered immediately after t=0, t=24, and t=48 hours of intraocular pressure (IOP) measurement. IOP was measured in both eyes at 0, 4, 8, 24, 48, 52, 56, and 72 hours after the baseline (t=0) IOP measurement. Mortality observations, clinical observations, eye irritation, and intraocular pressure were monitored, recorded, or measured throughout the survival portion of the study. All treatments were administered in the form of eye drops (1 drop / eye). Each animal was sedated using approximately 5 mg / kg of ketamine HCl intramuscularly (IM), with the goal of using the minimum necessary dose to achieve acceptable sedation for IOP measurements and drug administration procedures. Model 30 Classic TMA pneumatonometer was used to non-invasively measure intraocular pressure (IOP) (Reichert, Inc, Depew, NY). One drop of ocular anesthetic (0.5% proparacaine) was applied topically to each eye and allowed to take effect for at least 30 seconds prior to each IOP measurement. Using the manual tonometry mode of the pneumatonometer and keeping the animal in an upright position, 3 independent measurements were obtained for each eye at each time point and averaged.
[0437] By directly adding 0.004% travoprost ( Three Rho kinase inhibitor (ROCKi) formulations were prepared by dissolving 0.5% ROCKi(rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride in a formulation of 1% 1% 2-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide (Z), 0.005% latanoprost (Xalatan) and 0.01% bimatoprost (Lumigan) and adjusting the final pH to 5.5. When tested according to the above procedure, significant IOP reductions were observed for each combination, greater than the reductions achieved by each component alone. Figure 1 The results are illustrated graphically in (data for individual compounds are not shown for clarity).
[0438] Example 5. Synergistic combination therapy
[0439] The topical pharmaceutical composition for reducing intraocular pressure is prepared by conventional methods and formulated as follows:
[0440]
[0441] Formulation 12 was prepared by adding boric acid, D-mannitol, and EDTA to a labeled 150 mL plastic container. 100 mL of purified water was then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 5% benzalkonium chloride, 0.4% stock solution of travoprost, and (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate were then added, the solution was stirred for an additional 10 minutes to dissolve, and the pH was adjusted to approximately 5.0.
[0442] Formulation 13 was prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 to a labeled 150 mL plastic container. 100 mL of purified water was then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 1.5% benzalkonium chloride, a stock solution of 0.4% travoprost, and ROCKi (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate were then added, the solution was stirred for an additional 10 minutes to dissolve, and the pH was adjusted to approximately 5.0.
[0443] For certain topical ophthalmic glaucoma medications, fixed dose formulations containing two compounds have been shown to be less effective than concomitant administration of the individual compounds. Using the protocol described in Example 4 above, an experiment was conducted to see if administration of a mixture of ROCKi and travoprost (Formulation 13) was less effective than concomitant administration of the individual compounds. Unexpectedly, not only was there no loss of efficacy with Formulation 13, but administration of the mixture resulted in a significantly better IOP response than concomitant administration of the two compounds (Formulation 12 and Suweitan Z) individually. Figure 2 The results are illustrated in graphs.
[0444] Example 6. Combination therapy
[0445] The topical pharmaceutical composition for reducing intraocular pressure is prepared by conventional methods and formulated as follows:
[0446]
[0447]
[0448] Formulation 14 was prepared by adding boric acid, D-mannitol, and EDTA to a labeled 150 mL plastic container. 100 mL of purified water was then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 5% benzalkonium chloride, 0.4% stock solution of latanoprost, and (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate were then added, the solution was stirred for another 10 minutes to dissolve, and the pH was adjusted to approximately 5.0.
[0449] Formulation 15 was prepared by adding boric acid, D-mannitol, PEG-400, EDTA, and Myrj-52 to a labeled 150 mL plastic container. 100 mL of purified water was then added to bring the solution to almost 100%. The solution was stirred for 10 minutes. 1.5% benzalkonium chloride, 0.4% stock solution of latanoprost, and ROCKi (S) -4- (3-amino-1- (isoquinolin-6-ylamino) -1-oxopropan-2-yl) benzyl 2,4-dimethylbenzoate were then added, the solution was stirred for another 10 minutes to dissolve, and the pH was adjusted to approximately 5.0.
[0450] Example 7. Combination therapy in humans
[0451] A sterile isotonic aqueous solution is prepared containing (rac)-2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide hydrochloride and travoprost at concentrations of 0.5% and 0.004%, respectively, and the following excipients: boric acid (NF), mannitol (USP), polyethylene glycol 400 (USP), polyoxyethylene (40) stearate (NF), edetate disodium (USP), water for injection (USP), and benzalkonium chloride (NF) 0.015% as a preservative. The product may be adjusted to pH 5.2-5.9 using NaOH (USP) and / or HCL (USP).
[0452] Using the above formulation, both eyes of a person diagnosed with elevated intraocular pressure (IOP) were treated once a day with approximately 35 microliters of drops for up to 28 days. Following this dosing regimen, IOP measurements showed a significant decrease from baseline.
[0453] Example 8. Exemplary Combination Therapies
[0454] Taiwan macaques (Macaca cyclopis) were used in this study, and animal identification consisted of uniquely numbered tattoos and color-coded cage cards. On the first day of the study, animals were at least 4 years old and weighed at least 4 kg. A paired study design was used to determine the efficacy and tolerability of ocular hypotensive drugs, in which qdAM was administered to one eye of each monkey for three days (n=6 / group), and the untreated contralateral eye served as an internal control. Each dose was administered immediately after t=0, t=24, and t=48 hours of IOP measurement. IOP was measured in both eyes at time points of 0, 4, 8, 24, 48, 52, 56, and 72 hours after the baseline (t=0) IOP measurement. Mortality observations, clinical observations, eye irritation, and intraocular pressure were monitored, recorded, or measured throughout the survival portion of the study. All treatments were administered as eye drops once a day (1 drop / eye) for three days. Each animal was sedated using approximately 5 mg / kg of ketamine HCl intramuscularly (IM), with the goal of using the minimum necessary dose to achieve acceptable sedation for IOP measurements and drug administration procedures. Model 30 Classic TM The pneumatonometer is used to noninvasively measure intraocular pressure (IOP) (Reichert, Inc, Depew, NY). The pneumatonometer is a well-studied and well-accepted example of an applanation tonometer. The instrument measures IOP by determining the area of the cornea that is applanated by a constant force. Model 30 Classic TM The pneumatonometer achieves this by applying a precise amount of applanation force using a floating pneumatic tube to make the measurement. One drop of ocular anesthetic (0.5% proparacaine) was applied topically to each eye and allowed to take effect for at least 30 seconds prior to each IOP measurement. Using the manual tonometry mode of the pneumatonometer and keeping the animal in an upright position, 3 independent measurements were obtained for each eye at all time points and averaged. For each period, dosing consisted of one drop (approximately 30 L) of the composition instilled into the right eye (OD) at t=0, 24, and 48 hours.
[0455] Three solutions were used for comparison in this study. A 0.02% PG324 ophthalmic solution was prepared as formulation PG324-CF01, which contained 0.02% (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate as active ingredient and 0.005% latanoprost, 4.7% D-mannitol, 0.05% boric acid, and 0.02% benzalkonium chloride (BAK), pH 5.0. A 0.02% AR-13324 ophthalmic solution was prepared as formulation CF324-01, which contained 0.02% (S)-4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate, 0.05% boric acid, 4.7% D-mannitol, and 0.015% BAK, pH 5.0. Xalatan ophthalmic solution was obtained from a supplier and contained sodium chloride, sodium dihydrogen phosphate monohydrate, sodium phosphate dibasic anhydrous, and 0.02% BAK added as a preservative, pH approximately 6.7.
[0456] In this unilateral treatment study, the treatment effect is the IOP difference (ΔIOP) between the treated eye and the untreated eye. The ΔIOP of each animal is calculated at each time point. At each observation time, the mean and variance (standard deviation of the mean) of the observed IOP and ΔIOP of each treatment group are calculated. The probability comparison of ΔIOP is performed using a single sample two-tailed paired Student t-test. Statistical significance is determined using a critical p-value of p<0.05.
[0457] Data were analyzed using GraphPad Prism statistical software (Windows version 4.03, GraphPad Software, Inc., San Diego CA). Some analyses, including the tables in Appendix C and additional figures, were generated using Microsoft Office Excel 2010 (Microsoft, Inc., Seattle, WA).
[0458] All three formulations produced highly statistically significant (p<0.01) reductions in IOP compared to the contralateral control eye at all post-dose time points during the study (Student paired t-test). The greatest reduction in IOP was obtained with 0.02% PG324 ophthalmic solution. ophthalmic solution or only 0.02% AR-13324, FDC produced a greater degree of IOP reduction ( Figure 3). After the last dose on Day 3, IOP reductions varied from: 2.0 to 2.1 mmHg with Xalatan ophthalmic solution; from 4.1 to 5.2 mmHg with 0.02% AR-13324 ophthalmic solution; and from 4.8 to 6.2 mmHg with 0.02% PG324 ophthalmic solution.
[0459] Example 9. Combination therapy in humans
[0460] A sterile isotonic aqueous solution is prepared containing (S)-2,4-dimethylbenzoic acid 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dimethanesulfonate and latanoprost at concentrations of 0.02% and 0.005%, respectively, and the following excipients: boric acid (NF), mannitol (USP), water for injection (USP), and benzalkonium chloride (NF) 0.02% as a preservative. The product may be adjusted to pH 5 using NaOH (USP) and / or HCL (USP).
[0461] Using the above formulation, both eyes of a person diagnosed with elevated intraocular pressure (IOP) were treated once a day with approximately 35 microliters of drops for up to one year. Following this dosing regimen, IOP measurements showed a significant reduction from baseline.
[0462] Example 10. Synthesis of ROCKi-Latanoprost Conjugate
[0463]
[0464]
[0465] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid methyl ester (2)
[0466]
[0467] To latanoprost free acid in MeOH at 0°C was added TMS-CH2N2 until the solution remained yellow. AcOH (2 drops) was added to quench the excess TMS-CH2N2, and the solvent was evaporated. Column chromatography 70%-100% EtOAc / hexanes afforded pure (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid methyl ester (2).
[0468] Preparation of (Z)-7-((1R,2R,3R,5S)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoic acid methyl ester (3)
[0469]
[0470] To (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid methyl ester (2) in CH2Cl2 cooled to 0°C was added 2,6-lutidine and TIPS-OTf and the solution was stirred at 0°C for 30 minutes and then at room temperature for 2.5 hours. The solution was poured into EtOAc and NH4Cl(sat) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated. Column chromatography with 10% EtOAc / hexanes afforded (Z)-methyl 7-((1R,2R,3R,5S)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoate (3).
[0471] Preparation of (Z)-7-((1R,2R,3R,5S)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoic acid (4)
[0472]
[0473] To 3 in THF / MeOH / H2O was added LiOH*H2O and the solution was stirred at room temperature overnight. The solution was poured into EtOAc and NH4Cl(sat) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated to give (Z)-7-((1R,2R,3R,5)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoic acid (4).
[0474] Preparation of (Z)-7-((1R,2R,3R,5S)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester (5)
[0475]
[0476] To 4 in pyridine was added tert-butyl 2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate, EDC and DMAP, the solution was flushed with argon, capped and stirred overnight. The mixture was poured into NaHCO3 (sat.), extracted with EtOAc, dried (Na2SO4), filtered and evaporated. Column chromatography 4% MeOH / CH2Cl2 and then 50% EtOAc / hexanes gave pure (Z)-4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-5-phenyl-3-(triisopropylsilyloxy)pentyl)-3,5-bis(triisopropylsilyloxy)cyclopentyl)hept-5-enoate (5).
[0477] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester (6)
[0478]
[0479] To 5 cooled to 0°C was added TBAF and the solution was stirred at 0°C for 5 minutes and at room temperature for 12 hours. The mixture was poured into NH4Cl(sat)-EtOAc, extracted with EtOAc, dried (Na2SO4), filtered and evaporated. Column chromatography 5-8% MeOH / CH2Cl2 gave pure (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester (6).
[0480] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dihydrochloride (7)
[0481]
[0482] To 6 in CH2Cl2 was added HCl (4N in dioxane) and the solution was stirred at room temperature for 2 hours. The solvent was evaporated to give (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoic acid 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dihydrochloride (7).
[0483] Example 11. Synthesis of ROCKi-fluprostenol conjugate
[0484]
[0485] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid methyl ester (9)
[0486]
[0487] To fluprostenol in MeOH at 0°C was added TMS-CH2N2 until the solution remained yellow. AcOH (2 drops) was added to quench the excess TMS-CH2N2, and the solvent was evaporated. Column chromatography 90%-100% EtOAc / hexanes afforded pure (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid methyl ester (9).
[0488] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid methyl ester (10)
[0489]
[0490] To (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid methyl ester (9) in CH2Cl2 cooled to 0°C was added 2,6-lutidine and TBS-OTf and the solution was stirred at 0°C for 30 minutes and then at room temperature for 12 hours. The solution was poured into EtOAc and NH4Cl(sat) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated. Column chromatography with 10% EtOAc / hexanes afforded (Z)-methyl 7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoate (10).
[0491] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid (11)
[0492]
[0493] To 10 in THF / MeOH / H2O was added LiOH*H2O and the solution was stirred at room temperature overnight. The solution was poured into EtOAc and NH4Cl(sat.) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated. Column chromatography 10% EtOAc / hexane 1.5% AcOH gave pure (Z)-7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid (11).
[0494] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxoprop-2-yl)benzyl ester (12)
[0495]
[0496] To 11 in pyridine was added tert-butyl 2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate, EDC and DMAP, the solution was flushed with argon, capped and stirred overnight. The mixture was poured into NaHCO3 (sat.), extracted with EtOAc, dried (Na2SO4), filtered and evaporated. Column chromatography using 4% MeOH / CH2Cl2 gave pure 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl (Z)-7-((1R,2R,3R,5S)-3,5-bis(tert-butyldimethylsilyloxy)-2-((R,E)-3-(tert-butyldimethylsilyloxy)-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoate (12).
[0497] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester (13)
[0498]
[0499] To 12 in THF cooled to 0°C was added TBAF and the solution was stirred at 0°C for 5 minutes and at room temperature for 12 h. The mixture was poured into NH4Cl(sat)-EtOAc and extracted with EtOAc. The EtOAc layer was then washed with NH4Cl(sat), dried (Na2SO4), filtered and evaporated. Column chromatography using 5-10% MeOH / CH2Cl2 gave pure (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxoprop-2-yl)benzyl ester (13).
[0500] Preparation of (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dihydrochloride (14)
[0501]
[0502] HCl (4N in dioxane) was added to 13 in CH2Cl2 and the solution was stirred at room temperature for 2 hours. The solvent was evaporated and column chromatography using 10-20% MeOH / CH2Cl2 gave pure (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)but-1-enyl)cyclopentyl)hept-5-enoic acid 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl ester dihydrochloride (14).
[0503] Example 12. Synthesis of ROCKi-AR-102 free acid conjugate
[0504]
[0505] Preparation of methyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (16)
[0506]
[0507] To AR-102 free acid (15) in MeOH at 0°C was added TMS-CH2N2 until the solution remained yellow. AcOH (2 drops) was added to quench the excess TMS-CH2N2, and the solvent was evaporated. Column chromatography (90%-100% EtOAc / hexanes) afforded pure methyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (16).
[0508] Preparation of methyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoate (17)
[0509]
[0510] To methyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (16) in CH2Cl2 cooled to 0°C was added 2,6-lutidine and TBS-OTf and the solution was stirred at 0°C for 30 minutes and then at room temperature for 12 hours. The solution was poured into EtOAc and NH4Cl(sat) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated. Column chromatography (10% EtOAc / hexanes) afforded methyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoate (17).
[0511] Preparation of 7-((1R,2R,3R,5S)-2-((R)-3-(Benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoic acid (18)
[0512]
[0513] To 17 in THF / MeOH / H2O was added LiOH*H2O and the solution was stirred at room temperature overnight. The solution was poured into EtOAc and NH4Cl(sat.) / HCl(1N) (3:1) and extracted with EtOAc. The organics were dried (Na2SO4), filtered and evaporated. Column chromatography (10% EtOAc / hexanes) 1.5% AcOH gave pure 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoic acid (18).
[0514] Preparation of 4-(3-(tert-butyloxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoate (19)
[0515]
[0516] To 18 in pyridine was added tert-butyl 2-(4-(hydroxymethyl)phenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate, EDC and DMAP, the solution was flushed with argon, capped and stirred overnight. The mixture was poured into NaHCO3 (sat.), extracted with EtOAc, dried (Na2SO4), filtered and evaporated. Column chromatography using 4% MeOH / CH2Cl2 gave pure 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-(tert-butyldimethylsilyloxy)propyl)-3,5-bis(tert-butyldimethylsilyloxy)cyclopentyl)heptanoate (19).
[0517] Preparation of pure 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (20)
[0518]
[0519] To 19 in THF cooled to 0°C was added TBAF and the solution was stirred at 0°C for 5 min and at room temperature for 12 h. The mixture was poured into NH4Cl(sat)-EtOAc and extracted with EtOAc. The EtOAc layer was then washed with NH4Cl(sat), dried (Na2SO4), filtered and evaporated. Column chromatography using 5-10% MeOH / CH2Cl2 gave pure 4-(3-(tert-butoxycarbonylamino)-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (20).
[0520] Preparation of 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (21)
[0521]
[0522] To 20 in CH2Cl2 was added 2,6-lutidine (11 eq) and TMS-OTF (11 eq) and the solution was stirred at room temperature for 40 min. The mixture was poured into NaHCO3 (sat.) and extracted with CH2Cl2. The organics were dried (Na2SO4), filtered and evaporated. THF and TBAF (1 eq.) were added to the crude mixture and the solution was stirred at room temperature for 15 min. The mixture was poured into NaHCO3 (sat.), extracted with CH2Cl2, dried (Na2SO4), filtered and evaporated. Column chromatography (20% MeOH / CH2Cl2) gave pure 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 7-((1R,2R,3R,5S)-2-((R)-3-(benzo[b]thiophen-2-yl)-3-hydroxypropyl)-3,5-dihydroxycyclopentyl)heptanoate (21).
[0523] Example 13. ROCKi - Prostaglandin Salt
[0524]
[0525] Preparation of the salt of 2-(dimethylamino)-N-(1-hydroxyisoquinolin-6-yl)-2-(thiophen-3-yl)acetamide and (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxyoct-1-enyl)cyclopentyl)hept-5-enoic acid (PGF2α) (23)
[0526] Add PGF2 to 22 in MeOH α and the solution was heated to about 70 °C to dissolve the starting material. The solvent was then evaporated to give salt 23.
[0527] Salts 24 and 25 were prepared similarly to salt 23. Salt 27 was prepared from 26 in the same manner except that heating was not performed.
[0528] Example 14. Synthesis of (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide dimethanesulfonate
[0529]
[0530] Synthesis of (S)-tert-butyl 2-(4-chlorophenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (29)
[0531] To (S)-3-(tert-butoxycarbonylamino)-2-(4-chlorophenyl)propanoic acid (28) (8.5 g, 28.4 mmol) in DMF cooled to 0°C was added 2,4,6-collidine and 2,2,2-trichloro-1,1-dimethylethyl chloroformate in DMF. Then, 6-aminoisoquinoline in DMF was added and the solution was stirred at 0°C for 2 h. The mixture was poured into NaHCO3 (sat.) and extracted with EtOAc. The organic layer was washed with H2O, dried (Na2SO4), filtered and evaporated to give crude 29. Column chromatography (30% EtOAc-hexanes) and recrystallization (EtOAc / hexanes) gave pure (S)-tert-butyl 2-(4-chlorophenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (29, 7.8 g, 64%, >99% S enantiomer).
[0532]
[0533] Synthesis of (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide dimethanesulfonate (30)
[0534] To tert-butyl (S)-2-(4-chlorophenyl)-3-(isoquinolin-6-ylamino)-3-oxopropylcarbamate (29, 7.8 g) was added CH2Cl2 and MsOH, and the solution was stirred at room temperature overnight. The solvent was evaporated and the crude 30 was dried under high vacuum. Recrystallization (isopropanol) and high vacuum drying gave pure (S)-3-amino-2-(4-chlorophenyl)-N-(isoquinolin-6-yl)propanamide dimesylate (30, 7.2 g, 77%, >99% S-enantiomer).
[0535] While the present disclosure has been described in detail and with reference to specific embodiments, it will be apparent to one skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the present disclosure.
Claims
1. A composition comprising: ( S 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and A prostaglandin selected from latanoprost and travoprost, or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1, comprising: a) ( S 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate dimethanesulfonate; and b) Latanoprost.
3. The composition according to claim 1 or 2, wherein The composition is a pharmaceutical composition.
4. The composition according to claim 1 or 2, wherein The composition further comprises at least one component selected from the group consisting of a buffer, a preservative, a viscosity increasing agent and a surfactant.
5. Use of the composition of one of claims 1 to 4 for the preparation of a medicament for treating an ophthalmic condition in a subject in need of treatment, wherein the ophthalmic condition is glaucoma.
6. The use according to claim 5, wherein The composition is topically administered to the eye of the subject.
7. Use of the composition of one of claims 1 to 4 for the preparation of a medicament for reducing intraocular pressure in a subject in need thereof.
8. The use according to claim 7, wherein The composition is topically administered to the eye of the subject.
